“Sequegenics” is implementing a new approach that dramatically reduces the cost of sequencing a human genome with long-read next generation sequencing technology. As a result, the company is changing the economics of long-read technology, turning it into a sustainable business.
400 million people around the world are diagnosed with rare genetic disorders and need to have their genomes sequenced. Long-read is the only available technology capable of detecting the pathogenic variant causing their disease. “Sequegenics” is working to establish itself as the first company to exclusively use long-read genome sequencing technologies. This will not only help advance the diagnosis of rare diseases but will also allow the company to become the technological liaison between patients, lacking accurate diagnosis, and the pharmaceutical and biotech industry developing new treatments for them.